APAC IPOs & Placements, Aequitas Research

Clarence Chu

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

ClouDr (智云健康) Pre-IPO - Strong Growth but Has Issues that Need to Be Clarified

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cloudr-group-limited" target="_blank" data-smartkarma-citation="entities:34459:1" rel="noopener">ClouDr Group (16897333D CH)</a> is looking to raise around US$100m in its upcoming Hong Kong IPO. </li>
<li>The firm is a digital chronic condition management solution provider and is market leader in China in terms of the number of SaaS installations in hospitals and pharmacies in 2020.</li>
<li>In this note, we will discuss ClouDr's recent PHIP updates. </li>
</ul>



ClouDr Group (16897333D CH) is looking to raise around US$100m in its upcoming Hong Kong IPO. 
The firm is a digital chronic condition management solution provider and is market leader in China in terms of the number of SaaS installations in hospitals and pharmacies in 2020.
In this note, we will discuss ClouDr's recent PHIP updates. 


ClouDr (智云健康) Pre-IPO - PHIP Updates - Mixed Results, Strong Growth Could Be Masking Some Volatility